JP2018528208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528208A5 JP2018528208A5 JP2018511210A JP2018511210A JP2018528208A5 JP 2018528208 A5 JP2018528208 A5 JP 2018528208A5 JP 2018511210 A JP2018511210 A JP 2018511210A JP 2018511210 A JP2018511210 A JP 2018511210A JP 2018528208 A5 JP2018528208 A5 JP 2018528208A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- composition
- item
- sdg
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 72
- SBVBJPHMDABKJV-PGCJWIIOSA-N secoisolariciresinol diglucoside Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)CC=2C=C(OC)C(O)=CC=2)=C1 SBVBJPHMDABKJV-PGCJWIIOSA-N 0.000 claims description 51
- SBVBJPHMDABKJV-UHFFFAOYSA-N secoisolariciresinol diglycoside Natural products C1=C(O)C(OC)=CC(CC(COC2C(C(O)C(O)C(CO)O2)O)C(COC2C(C(O)C(O)C(CO)O2)O)CC=2C=C(OC)C(O)=CC=2)=C1 SBVBJPHMDABKJV-UHFFFAOYSA-N 0.000 claims description 48
- 230000032683 aging Effects 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 21
- 230000005855 radiation Effects 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000009758 senescence Effects 0.000 claims description 6
- 208000004852 Lung Injury Diseases 0.000 claims description 5
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 5
- 238000002405 diagnostic procedure Methods 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 231100000515 lung injury Toxicity 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 238000002591 computed tomography Methods 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 229910052704 radon Inorganic materials 0.000 claims description 2
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 claims description 2
- PUETUDUXMCLALY-HOTGVXAUSA-N (-)-secoisolariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 PUETUDUXMCLALY-HOTGVXAUSA-N 0.000 description 12
- DWONJCNDULPHLV-HOTGVXAUSA-N Enterodiol Chemical compound C([C@@H](CO)[C@H](CO)CC=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 DWONJCNDULPHLV-HOTGVXAUSA-N 0.000 description 12
- AOJXPBNHAJMETF-UHFFFAOYSA-N Enterodiol Natural products OCC(Cc1ccc(O)cc1)C(CO)Cc2ccc(O)cc2 AOJXPBNHAJMETF-UHFFFAOYSA-N 0.000 description 12
- HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 description 12
- HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 description 12
- OGFXBIXJCWAUCH-UHFFFAOYSA-N meso-secoisolariciresinol Natural products C1=2C=C(O)C(OC)=CC=2CC(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-UHFFFAOYSA-N 0.000 description 12
- 235000004239 secoisolariciresinol Nutrition 0.000 description 12
- 230000000975 bioactive effect Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229940107657 flaxseed extract Drugs 0.000 description 6
- 235000020704 flaxseed extract Nutrition 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940056692 resinol Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562212898P | 2015-09-01 | 2015-09-01 | |
| US62/212,898 | 2015-09-01 | ||
| PCT/US2016/049780 WO2017040718A1 (en) | 2015-09-01 | 2016-08-31 | USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION DAMAGE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528208A JP2018528208A (ja) | 2018-09-27 |
| JP2018528208A5 true JP2018528208A5 (enExample) | 2019-10-10 |
Family
ID=58188252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511210A Pending JP2018528208A (ja) | 2015-09-01 | 2016-08-31 | 放射線損傷からの保護のためのセコイソラリシレシノールジグルコシド（ｓｄｇ）および関連化合物の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180243327A1 (enExample) |
| EP (1) | EP3344271A4 (enExample) |
| JP (1) | JP2018528208A (enExample) |
| KR (1) | KR20180041742A (enExample) |
| CN (1) | CN108697748A (enExample) |
| AU (1) | AU2016315952A1 (enExample) |
| CA (1) | CA2997112A1 (enExample) |
| IL (1) | IL257780A (enExample) |
| MA (1) | MA45520A (enExample) |
| WO (1) | WO2017040718A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200268779A1 (en) * | 2017-09-27 | 2020-08-27 | The Trustees Of The University Of Pennsylvania | USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION-INDUCED CARDIOVASCULAR DYSFUNCTION |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3065925B2 (ja) * | 1996-01-30 | 2000-07-17 | 日清製油株式会社 | 活性酸素種消去剤及び退色防止剤 |
| US20040156881A1 (en) * | 2001-04-04 | 2004-08-12 | Aedin Cassidy | Use of lignans in foods |
| US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
| US7776915B2 (en) * | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
| US10045951B2 (en) * | 2007-05-25 | 2018-08-14 | The Trustees Of The University Of Pennsylvania | Flaxseed lignan complex and its use thereof |
| US10449224B2 (en) * | 2007-05-25 | 2019-10-22 | The Trustees Of The University Of Pennsylvania | Flaxseed lignan complex, methods of using and compositions thereof |
| AU2009279676C1 (en) * | 2008-08-07 | 2015-08-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Radioprotectants targeting thrombospondin-1 and CD47 |
| US8575563B2 (en) * | 2009-11-02 | 2013-11-05 | Procure Treatment Centers, Inc. | Compact isocentric gantry |
| PT3007557T (pt) * | 2013-06-10 | 2018-11-09 | Scripps Research Inst | Preparação do diglucosídeo (s,s)-secoisolariciresinol e do diglucosídeo (r,r)-secoisolariciresinol |
-
2016
- 2016-08-31 KR KR1020187008184A patent/KR20180041742A/ko not_active Withdrawn
- 2016-08-31 AU AU2016315952A patent/AU2016315952A1/en not_active Abandoned
- 2016-08-31 WO PCT/US2016/049780 patent/WO2017040718A1/en not_active Ceased
- 2016-08-31 CN CN201680055155.2A patent/CN108697748A/zh active Pending
- 2016-08-31 MA MA045520A patent/MA45520A/fr unknown
- 2016-08-31 JP JP2018511210A patent/JP2018528208A/ja active Pending
- 2016-08-31 US US15/757,273 patent/US20180243327A1/en not_active Abandoned
- 2016-08-31 CA CA2997112A patent/CA2997112A1/en not_active Abandoned
- 2016-08-31 EP EP16842946.2A patent/EP3344271A4/en not_active Withdrawn
-
2018
- 2018-02-27 IL IL257780A patent/IL257780A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dubin et al. | Quality‐of‐life in patients receiving implantable cardioverter defibrillators at or before age 40 | |
| JP2017520620A5 (enExample) | ||
| CA2761156A1 (en) | Methods of preventing ischemic injury using peripheral nociceptive stimulation | |
| ES2374199T5 (es) | Fármaco para la ralentización del corazón que contiene beta bloqueante de acción corta como principio activo | |
| Son et al. | SAMiRNA targeting amphiregulin alleviate total-body-irradiation-induced renal fibrosis | |
| Hong et al. | Time, dose, and volume responses in a mouse pulmonary injury model following ablative irradiation | |
| JP2018528208A5 (enExample) | ||
| JP2014201591A (ja) | 医用画像処理電離放射線被曝の長期的および短期的な有害な影響をゲニステインの投与により軽減する方法 | |
| CN118434472A (zh) | 利用flash放射疗法进行处理的方法和装置 | |
| Chu et al. | Skeletal response to Yoda1 and whole-body vibration in mice varied with animal age, bone compartment, treatment duration, and radiation exposure | |
| Manapov et al. | Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest | |
| Eyster | Local thiabendazole in the treatment of creeping eruption | |
| Han et al. | Routine preprocedural transesophageal echocardiography might not be necessary for stroke prevention evaluation in AF patients on anticoagulation therapy | |
| US9877976B2 (en) | Methods and compositions for protection of cells and tissues from computed tomography radiation | |
| Teimouri et al. | Investigation of electrocardiography and echocardiography changes after adjuvant radiation therapy of left-sided breast cancer | |
| US20180243327A1 (en) | USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION DAMAGE | |
| TWI848607B (zh) | 一種次氯酸組合物用於製備預防、改善或治療放射性皮膚炎之醫藥組合物的用途 | |
| Ung et al. | AML-080 superior anti-leukemic effects of combined acid ceramidase and bcl-2 inhibition in acute myeloid leukemia | |
| Delavari et al. | Patients’ radiation exposure during various types of cardiac arrhythmias ablation | |
| Kottou et al. | [OA193] Patient dosimetry during cone beam ct in dental implant planning | |
| JP2020535178A (ja) | 放射線誘発心血管障害に対する保護のためのセコイソラリシレシノールジグルコシド（ｓｄｇ）及び関連化合物の使用 | |
| Sundaram et al. | Radiation exposure in cardiac electrophysiology: a prospective observational study in a tertiary care centre | |
| Ardawi et al. | Vitamin-D inadequacy in Saudi postmenopausal women with osteoporosis | |
| Ishibashi et al. | National Survey on Procedure Dose of Endovascular Treatment for Lower Extremity Artery Disease | |
| Suliman et al. | First survey of mammography practice in sudan: Radiation exposure and setting national diagnostic reference levels |